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sicians in 8 European countries. 171 specialists completed patient record forms 
(PRFs) on 969 individuals diagnosed with PV including details of diagnosis, con-
comitant conditions, symptoms, laboratory values and treatment history. Data for 
patients currently receiving HU therapy for more than 3 months were compared 
with 4 elements of the ELN consensus paper (need for phlebotomy, uncontrolled 
myeloproliferation, failure to reduce massive splenomegaly and presence of leg 
ulcers). Results: 499 of the 969 patients (51%) were currently receiving HU for a 
period of more than 3 months. They had a mean age of 68.5 years and had been 
diagnosed for an average of 39.1 months; 58% were male. Based on the ELN con-
sensus criteria published by the British Journal of Haematology (Barosi et al, 2009), 
200 (40%) of those currently receiving HU are classified as resistant/intolerant to 
HU-therapy. 139 patients (70%) were receiving phlebotomy on average 3.4 times in 
the past 6 months, 61 (31%) had uncontrolled myeloproliferation (platelet count 
greater than 400x 109/L and white blood cell count greater than 10x 109/L), 5 (3%) 
had ulcers and 1 (1%) had massive splenomegaly. 102 (51%) physicians reported that 
they are not completely satisfied with HU treatment, with inadequate response 
the main cause of dissatisfaction. ConClusions: This analysis indicates that a 
proportion of patients continue to receive HU therapy despite being classified as 
resistant/intolerant according to the ELN consensus paper and a lack of satisfaction 
amongst physicians. The data support the need for more drug options in later lines 
of therapy, for patients resistant/intolerant to HU therapy.
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objeCtives: EGFR mutation-positive NSCLC represents a distinct subtype of NSCLC 
and its first-line treatment generally comprises erlotinib, gefitinib or afatinib. These 
agents have all shown progression-free survival improvement vs platinum-doublet 
chemotherapy (CT). However, a recent pair-wise meta-analysis of phase III clini-
cal trials based on individual patient-level data (n= 1231) demonstrated that the 
reversible EGFR TKIs, erlotinib and gefitinib, do not prolong overall survival (OS) vs 
CT, neither for the overall patient population nor for the individual mutation sub-
types, exon 19 deletions (Del19) and L858R.1 Here, we present a broader pair-wise 
meta-analysis including studies of the irreversible ErbB family blocker afatinib vs 
CT, as well as studies of erlotinib and gefitinib. Methods: Patients with common 
EGFR mutations (Del19 or L858R) treated with either afatinib (LUX-Lung 3, LUX-Lung 
6), erlotinib (ENSURE, EURTAC, OPTIMAL) or gefitinib (IPASS, NEJ002, WJTOG3405) 
in phase III clinical trials vs CT were included. Pooled treatment estimates using 
the inverse variance weighted method were calculated for all TKI vs CT compari-
sons in patients with Del19 or L858R. Results: In total, data from 1037 patients 
with Del19 and 816 patients with L858R mutations were analyzed. Afatinib sig-
nificantly improved OS vs CT in patients with Del19 (HR [95% CI]: 0.59 [0.45‒0.77]). 
For patients with Del19 there was no significant difference in OS, compared with 
CT, for either erlotinib (HR [95% CI]: 1.03 [0.77‒1.38]) or gefitinib (HR [95% CI]: 0.90 
[0.70‒1.17]). None of the agents improved OS vs CT in patients with L858R muta-
tions (afatinib: HR [95% CI] 1.25 [0.91‒1.71]; erlotinib: 0.98 [0.72‒1.35]; gefitinib: 1.11 
[0.81‒1.54]). ConClusions: No differences in OS were observed in the overall EGFR 
mutation-positive or the L858R population for afatinib, erlotinib, or gefitinib. In con-
trast to other TKIs, afatinib showed a significant OS benefit vs CT in Del19 patients. 
1Lee C, et al. J Clin Oncol 2015;33(suppl):abstract 8072
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objeCtives: To compare the efficacy of available treatments in patients with previ-
ously treated advanced/metastatic non-small cell lung cancer (NSCLC) Methods: 
Clinical trials of ceritinib, crizotinib, pemetrexed, docetaxel, erlotinib, and best sup-
portive care (BSC) in previously treated, crizotinib-naïve NSCLC were identified in 
a systematic literature review (up to March 2014). Since only single-arm trials were 
available for ceritinib, a matching-adjusted indirect comparison between ceritinib 
trials and similarly-designed crizotinib trials was used to link ceritinib into the 
evidence network. A Bayesian-based network meta-analysis (NMA) was then con-
ducted to compare overall survival (OS), progression-free survival (PFS) and overall 
response rate (ORR) among the studied treatments. Relative treatment effects and 
corresponding 95% credible intervals (CrIs) were estimated as well as the posterior 
efficacy rankings. Results: Fourteen clinical trials, including two ceritinib single-arm 
trials (ASCEND-1 [NCT01283516], ASCEND-3 [NCT01685138]), were included. Sample 
sizes ranged from 49 to 488 patients per arm. Ceritinib was associated with signifi-
cantly prolonged OS compared to crizotinib (hazard ratio [HR]: 0.58; 95%CrI: 0.41-0.83), 
pemetrexed (0.44; 0.26-0.76), docetaxel (0.47; 0.28-0.82), erlotinib (0.44; 0.26-0.80), and 
BSC (0.29; 0.16-0.55). Ceritinib also showed improved PFS compared to crizotinib (0.45; 
0.18-1.56), pemetrexed (0.18; 0.06-0.83), docetaxel (0.17; 0.06-0.84), erlotinib (0.15; 0.05-
0.90), and BSC (0.08; 0.02-0.69). Ceritinib increased the odds of achieving ORR by 38% 
compared to crizotinib, and was associated with ≥ 3 times higher ORR compared 
to other treatments. Ceritinib was the most efficacious treatment in terms of OS 
(posterior probability 99%), PFS (92%) and ORR (63%) among all treatments, followed 
pany. Results: Publicly-available guidance on RWE data collection by HTA and 
reimbursement authorities is almost entirely lacking, with the exception of The 
Netherlands, where there is a well-established process for post-launch data col-
lection. Published data sources were limited to two studies, both with a focus on 
safety. Market access specialists highlighted five categories of RWE data types. All 
countries expressed a requirement for patient characteristics, treatment patterns 
and effectiveness. Resource use and quality of life were considered supportive 
but not essential. A current or planned melanoma registry was identified in most 
countries, but the range of data collected and national coverage varied substan-
tially. ConClusions: There is very little formal guidance on RWE requirements in 
Europe, and no consistency across countries. In some cases (France, Germany, The 
Netherlands), there is an established infrastructure, although there is substantial 
variation between countries. Market access specialists anticipate increasing require-
ments for RWE in coming years but, currently, such data can be considered sup-
portive rather than essential. Therefore, manufacturers with new or development 
drugs must anticipate future, expanding requirements for RWE in their post-launch 
data generation programmes.
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objeCtives: To determine country-specific requirements for real-world evidence 
(RWE) in Europe to support ongoing market access for new drugs to treat non-
small cell lung cancer (NSCLC). Several new classes of drugs for NSCLC are coming 
to market and there is likely to be much competition. RWE is expected to play an 
important part in differentiating the new products and their most suitable target 
patient populations. Methods: We reviewed published health technology assess-
ments (HTAs) and reimbursement agency web sites to determine data sources for, 
or guidance on, RWE in France, Germany, Italy, The Netherlands, Spain, Sweden and 
the UK. In addition, we performed a pragmatic review of peer-reviewed literature 
to identify types of NSCLC RWE being published, and collected the views of market 
access specialists on RWE requirements among country representatives of a global 
pharmaceutical company. Results: Publicly-available guidance on NSCLC RWE 
data collection by HTA and reimbursement authorities is currently lacking. Likewise, 
data sources are highly limited in number and scope and there were no publications 
featuring feasible registries. Market access specialists highlighted five categories of 
RWE data types. All countries expressed a requirement for patient characteristics, 
treatment patterns and effectiveness. Resource use and quality of life were con-
sidered supportive but not essential. No current registries are able to meet these 
requirements. ConClusions: Formal guidance on RWE requirements in NSCLC in 
Europe is lacking and there is a need for registries to capture the range of data types 
highlighted by market access specialists to obtain and maintain market access. 
Given the level of development in the NSCLC field, and the number of likely new 
market entrants, manufacturers with new or developmental drugs need to help 
establish an infrastructure for collecting NSCLC RWE in Europe.
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objeCtives: Polycythemia Vera (PV) is associated with an overproduction of blood 
cells which leads to increased risk of blood clots and associated cardiovascular (CV) 
complications and may result in increased morbidity and mortality. This analy-
sis seeks to evaluate the impact of Hydroxyurea (HU) treatment on symptoms, 
concomitant conditions and cardiac risk. Methods: Data was drawn from the 
Adelphi PV Disease Specific Programme, a cross sectional survey of physicians in 
8 European countries. 171 specialists completed patient record forms (PRFs) on 
969 individuals diagnosed with PV including details of concomitant conditions, 
symptoms, treatment history, cardiac and/or thrombosis risk status and control 
status (both defined by the physician). Each physician completed a PRF for the last 6 
consulting patients. Results: 499 patients currently receiving HU treatment, for at 
least 3 months post diagnosis, were included in the analysis. At diagnosis 348 (70%) 
patients presented as symptomatic, 174 (35%) experienced headaches, 168 (34%) 
fatigue/weakness/tiredness and 166 (33%) pruritus/itching. 328 (66%) had concomi-
tant conditions, principally hypertension 204 (41%) and hyperlipidaemia 106 (21%). 
277 (56%) patients presented with splenomegaly with 99 (20%) reporting this as mod-
erate/massive. Cardiac events and/or thrombosis risk was reported as high in 283 
(57%) patients. Despite current use of HU, 216 (43%) patients are reported as being 
symptomatic, 110 (22%) due to fatigue/weakness/tiredness, 44 (9%) pruritus/itching 
and 34 (7%) headache. 306 (61%) experience concomitant conditions with hyperten-
sion remaining a problem for 186 (37%) patients. 51 (10%) patients report moderate/
massive splenomegaly whilst CV risk remains high for 156 (31%) of patients. 86 (17%) 
patients are not currently considered to be controlled. ConClusions: These find-
ings indicate that HU fails to adequately reduce cardiac risk in a proportion of PV 
patients. Despite treatment almost 1/5 (17%) patients were not considered to be con-
trolled and 2/5 (43%) reported symptoms; hence need exists for better treatments.
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objeCtives: Assess the level of resistance/intolerance to Hydroxyurea (HU) therapy 
in Polycythemia Vera (PV) patients in the real world setting across Europe, based on 
the European Leukemia Net (ELN) consensus paper. Methods: Data was drawn 
from the Adelphi PV Disease Specific Programme, a cross-sectional survey of phy-
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patient registry is the first step towards generating outcome data in terms of costs 
and effectiveness in later stage.
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objeCtives: This study aims to evaluate the impact of cancer and its treatment on 
HbA1c-values among individuals with colorectal cancer (CRC) using glucose lower-
ing drugs (GLDs). Methods: Patients with primary CRC (1998-2011) were selected 
from the Eindhoven Cancer Registry and linked to the PHARMO Database Network 
including out-patient pharmacy and clinical laboratory data. Patients with more 
than two years of GLDs use prior to cancer diagnosis were included. Linear mixed 
effects models were conducted to evaluate changes in HbA1c for colon cancer (CC) 
and rectal cancer (RC) patients in the four years around CRC diagnosis. Results: Of 
all CRC patients (n= 4,714), 294 (6%) GLDs users with CC and 144 (3%) with RC were 
selected. In the crude model, mean HbA1c at cancer diagnosis was 6.9% (51.6 mmol/
mol) among CC patients and 7.1% (53.5 mmol/mol) among RC patients. Among 
CC patients, HbA1c decreased with 0.12% per year (p= 0.0002) before cancer diag-
nosis in the adjusted model and after diagnosis it increased with 0.12% per year 
(p= 0.02). In subgroup analyses, effects on HbA1c were more pronounced in users 
of anti-anaemic preparations, these preparations are suggested to interfere with 
HbA1c. Among RC patients, HbA1c decreased before diagnosis with 0.18% per year 
(p= 0.0006), whereas after diagnosis it changed not-significantly. ConClusions: 
Among users of GLDs, HbA1c decreased with 0.12%-0.18% (1-2 mmol/mol) per year 
before CRC diagnosis. Only among CC patients, HbA1c increased after diagnosis 
(0.12% per year; 1.3 mmol/mol). In (un)diagnosed cancer patients the HbA1c measure 
to visualise glycaemic control might be influenced by anti-anaemic preparations.
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objeCtives: Castration resistant prostate cancer (CRPC), which occurs in 10-20% of 
patients with prostate cancer (PC), has had a historically poor prognosis. However, 
there are a number of emerging treatment options. The aim of this study was to 
describe the real-world treatment patterns of CRPC in Japan. Methods: A retrospec-
tive chart review of patients with mCRPC (N= 445) was conducted from December 
2014 to February 2015 with urologists (N= 176) from online physician panels. Charts 
from the most recent patient visits meeting the inclusion criteria were used. Patient 
demographics, health history, healthcare resource use, treatment information, and 
clinical outcomes were entered into an online data collection form. Results: Patients 
(N= 445) were an average of 73.57 years old (SD= 8.34), had been diagnosed with PC 
for 5.12 years (SD= 6.22), and had been castration resistant for 2.31 years (SD= 1.98). 
Androgen deprivation therapy was used among 43.64% of patients in 1st line and 
40.68% in 4th line. Enzalutamide and abiraterone were also common, though more 
so in later lines because of their recent availability (used among 14.46% and 8.73%, 
respectively, of patients in 1st line and 40.68% and 20.34%, respectively, in 4thline). 
NSAIDs and opioids were used frequently for pain management. The presence of 
symptomatic skeletal events (SSEs) was uncommon (2-3% within each treatment 
line) but associated with an increased use of opioids, strontium-89, bisphosphonates, 
and NSAIDs (all p< .05). Patients who experienced an SSE at any point (N= 24) reported 
significantly more annualized post-SSE physician visits (Adjusted means= 23.46 vs. 
12.13) and general ward hospitalizations (Adjusted means= 2.23 vs. 0.71) than those 
without an SSE (N= 421; all p< .05). ConClusions: Novel anti-hormone therapies are 
widely accepted in clinical practice, becoming more common than chemotherapy. 
The results also suggest that SSEs are associated with more medical resources and 
analgesics, highlighting the unmet medical needs for treatment of bone metastases.
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objeCtives: To control such cancer pain, it is necessary to select analgesics depend-
ing on the intensity of cancer pain, referring to the WHO-recommended 3 step anal-
gesic ladder. This study aimed to provide the Use pattern narcotic analgesics for 
cancer patient in Korea using claims data. Methods: To define terminal cancer and 
severely ill patients close to death who are assumed to be suffering severe pain, 0~120 
year old cancer patients who received at least one prescription of a ‘C00-C99’code 
within top 6 ranks of main disease code and subordinate disease code over 4 years 
between 2008 and 2011 have been examined. Among those patients, 203,493 patients 
who confirmed as ‘Death’ in the clinical endpoint and had the date of death were 
defined as cancer deaths. The status of their narcotic analgesics use was analyzed at 
1 month prior to death, 2 months before death, and 3 months before death. Results: 
The use rate of narcotic analgesics in cancer deaths at 1 month prior to death was 
82.6% (168,002 patients). By level of a healthcare facility, prescription frequency was 
the highest for Morphine, followed by Fentanyl, and Oxycodone for hospital or higher 
levels at 1 month prior to death. However, Tramadol was most frequently prescribed 
in nursing hospitals and clinics. And Pethidine which is not a recommended narcotic 
analgesic for cancer pain patients was prescribed for 38.5% of the entire narcotic 
analgesic users. The daily amount of narcotic analgesics at 1 month before death is 
by crizotinib. ConClusions: In this NMA of treatments for patients with previ-
ously treated advanced/metastatic NSCLC, ceritinib was associated with significantly 
reduced risks of death or progression, by 40-85%, and with higher ORR, compared 
with other active treatments. Comparisons of non-randomized treatment groups are 
limited by the potential for confounding due to unadjusted cross-study differences.
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objeCtives: In USA, there are 221,200 estimated new cases of lung cancer and 
158,040 deaths due to lung cancer in 2015. Lung cancer accounts for about 27% 
of all cancer deaths and is the leading cause of cancer death. Non-small cell lung 
cancer (NSCLC) constitutes about 85-90% of all lung cancer cases. Objective of this 
study was to assess the incremental value of survival and cost of care in NSCLC 
patients treated with photodynamic therapy (PDT), compared to radiation and abla-
tion therapy. Methods: Retrospective analysis using SEER-Medicare linked data. 
Patients with NSCLC diagnosed between 2000 and 2007 (n= 221195) were identi-
fied and retrospectively followed for one-year pre and three-year post diagnosis. 
We analyzed survival length and cost over the follow-up period for three groups: 
PDT with radiation, ablation with radiation and radiation alone. Variation in health 
service use and cost was analyzed across phases of care. We used Cox proportional 
hazard model to assess mortality (all-cause and lung cancer-specific); we employed 
generalized linear models to study total costs in follow-up period. Results: Of 
the NSCLC cohort, 51382 had radiation therapy alone, 78 received PDT with radia-
tion, and 208 received ablation with radiation. Mean survival (in days) was highest 
for PDT with radiation patients (mean 537, std 491), followed by radiation alone 
group (mean 452, std 595), and lowest for ablation with radiation group (mean 349, 
std 465). Total cost over follow-up period was highest for ablation with radiation 
group, compared to the radiation alone group, after controlling for demographic 
and clinical covariates (beta estimate= 0.5536, SE= 0.0847, p< .0001). ConClusions: 
Among NSCLC patients, addition of PDT improved survival. Total cost was higher 
for those receiving ablation with radiation, compared to those receiving radiation 
alone. Future research should address the comparative effectiveness to understand 
the ultimate clinical implications of PDT therapy for NSCLC patients.
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objeCtives: Effects of malnutrition in patients with colorectal cancer (CRC) are 
often disregarded. This abstract aims to report nutritional supplement (NS) usage in 
CRC patient with abdominal resection surgery (ARS) in Turkey using general health 
insurance (GHI) reimbursement database of Social Security Institute (SSI). Methods: 
Turkish GHI system has covered 98% of total population of Turkey. Therefore statistics 
obtained via the GHI database are highly representative of the population of Turkey. 
From GHI database, patient with CRC (by using ICD-10 code) who underwent any kind 
of ARS (by using relevant codes in national medical procedures code book) between 
1jan2009 and 31dec2013 were included to analysis. Results: Of 42,970 CRC patients 
with ARS in database, 27,471 patients (mean age: 61.5 years, 42.7% female and 2.0% 
used pre-operative chemotherapy) met selection criteria of this abstract. NS was 
used 6.3% of the patients during hospitalization (median 12.0 days) and NS was used 
median 2.0 days during hospitalization. Mortality rate was 4.6% during hospitaliza-
tion. Of the 26,203 discharged patients, 1.7% used NS during outpatient follow-up 
duration and 1.3% used NS more than 30 days based on prescribing data. Moreover, 
97.3% of patients who received NS during hospitalization did not continue NS usage 
during outpatient follow-up duration. Median survival durations were 60.0 and 47.7 
months in patients not used NS and used NS, and 12-month survival rates were 
80.0% and 68.0%, respectively. ConClusions: The abstract showed NS usage pat-
terns in CRC patients with ARS in Turkey. Although malnutrition risk in CRC patients 
has been reported to be high, NS usage ratio is low and usage duration is relatively 
short. Moreover survival analyses revealed that NS seems to be given to patients with 
advanced stage of CRC. In conclusion strategies to increase usage of malnutrition 
diagnosis and treatment algorithm should be developed.
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objeCtives: This cross-sectional study (CSS) aims to calculate the incidence 
rates of all cancer types in Egypt as well as typography breakdown of each cancer 
type. Methods: Data of 40,477 patients were collected from Tanta Cancer Center 
retrospectively to form the largest population-based cancer registry in Egypt covering 
a period of 9 years. The cancer incidence rates are calculated based on population of 
Gharbiah (as an indicator for rates in Egypt) and based on number of cases of each 
cancer type there. Results: Breast cancer is considered to be the major cancer type 
with 18% (99% CI= 16.6%-19.4%) (n= 7332) share of total cancer cases, followed by liver 
cancer: 10.5% (99% CI= 8.6%-12.4%) (n= 4265). Bladder cancer’s share is: 8.7% (99% CI= 
6.6%-10.8%) (n= 3521) followed by lymph node, lung, and blood cancers: 8.1% (99% 
CI= 5.9%-10.3%) (n= 3270), 6.2% (99% CI= 3.7%-8.7%) (n= 2512) and 6.05% (99% CI= 
3.55%-8.55%) (n= 2449) respectively. The age standardized incidence rates are high-
est for breast cancer (33.8), liver cancer (25.5) and bladder Cancer (16.5). Worldwide, 
Egypt is considered to have higher rates for liver and bladder cancers than other 
countries all over the world. Projections for cancer incidence rates in the future can 
be drawn as well in the registry till the year 2025. ConClusions: In the lack of any 
accurate data in the time being, this CSS registry provides a well-designed guide 
for decision makers about the actual weight for each cancer type in Egypt Also this 
